ACQUIRED RESISTANCE TO PD-(L)1 BLOCKADE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ricciuti, Biagio [1 ]
Lamberti, Giuseppe [1 ]
Alessi, Joao Victor [1 ]
Pecci, Federica [1 ]
Di Federico, Alessandro [1 ]
Wang, Xinan [2 ]
Barrichello, Adriana [1 ]
Vaz, Victor [1 ]
Pangilinan, Andy [1 ]
Haradon, Danielle [1 ]
Elinton, Lee [1 ]
Nishino, Mizuki [3 ]
Rodig, Scott [3 ]
Sholl, Lynette [3 ]
Awad, Mark [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
528
引用
收藏
页码：A553 / A554
页数：2
相关论文
共 50 条
  • [21] PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
    Samaneh Moradi
    Pedram Sarikhani
    Rafid Jihad Albadr
    Waam Mohammed Taher
    Mariem Alwan
    Mahmood Jasem Jawad
    Hiba Mushtaq
    Niyousha Vakilzadehian
    Discover Oncology, 16 (1)
  • [22] Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
    Gong, Bo
    Kiyotani, Kazuma
    Sakata, Seiji
    Nagano, Seiji
    Kumehara, Shun
    Baba, Satoko
    Besse, Benjamin
    Yanagitani, Noriko
    Friboulet, Luc
    Nishio, Makoto
    Takeuchi, Kengo
    Kawamoto, Hiroshi
    Fujita, Naoya
    Katayama, Ryohei
    JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 216 (04): : 982 - 1000
  • [23] Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
    Luo, Jia
    Bandlamudi, Chaitanya
    Ricciuti, Biagio
    Vokes, Natalie
    Schoenfeld, Adam Jacob
    Egger, Jacklynn, V
    Sauter, Jennifer L.
    Plodkowski, Andrew J.
    Preeshagul, Isabel Ruth
    Kris, Mark G.
    Van Allen, Eliezer Mendel
    Taylor, Barry S.
    Rizvi, Hira
    Donoghue, Mark
    Awad, Mark M.
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [25] Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer
    Zhang, Yan
    Doran, Charlotte
    Le, Trong Kim
    Dreyfus, Brian
    Kola, Nina
    Sylvester, Brooke E.
    Lal, Lincy
    Penrod, John R.
    Shropshire, Stephanie Meadows
    FUTURE ONCOLOGY, 2023, : 4509 - 4523
  • [26] Impact of STK11 copy loss on clinical outcomes to PD-(L)1 blockade in non-small cell lung cancer.
    Gutierrez, Catherine
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Pecci, Federica
    De Castro Barrichello, Adriana Paula
    Vaz, Victor R.
    Sholl, Lynette M.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Sensitivity of a PD-L1-Analysis in Patients with non-small cell Lung Cancer (NSCLC) with Pleural Effusion
    Hagmeyer, L.
    Treml, M.
    Richter, K.
    Hekmat, K.
    Heldwein, M.
    Schaefer, S.
    Buettner, R.
    Randerath, W. J.
    PNEUMOLOGIE, 2020, 74 : S40 - S41
  • [28] PD-L1 Expression in Patients with Non-small Cell Lung Cancer
    Masago, Katsuhiro
    Fujita, Shiro
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Katakami, Nobuyuki
    Hirata, Yukio
    ANTICANCER RESEARCH, 2017, 37 (05) : 2269 - 2274
  • [29] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
  • [30] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
12345